1. Volume 377, Issue 9783, Pages 2103-2114 (June 2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial 
Prof Timothy S Maughan, FRCR, Richard A Adams, FRCP, Christopher G Smith, BSc, Angela M Meade, DPhil, Prof Matthew T Seymour, FRCP, Richard H Wilson, MD, Shelley Idziaszczyk, MPhil, Rebecca Harris, MSc, David Fisher, MSc, Sarah L Kenny, MSc, Edward Kay, BA, Jenna K Mitchell, BHSc, Ayman Madi, MRCP, Prof Bharat Jasani, FRCPath, Michelle D James, BSc, John Bridgewater, MD, M John Kennedy, MD, Bart Claes, MSc, Diether Lambrechts, PhD, Prof Richard Kaplan, MD, Prof Jeremy P Cheadle, PhD 
The Lancet 
Volume 377, Issue 9783, Pages (June 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile EGFR=epidermal growth factor receptor.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier overall survival curves for patients with (A) KRAS wild-type, (B) KRAS mutant, (C) BRAF mutant and KRAS wild-type, and (D) KRAS, NRAS, and BRAF all wild-type tumours
HR=hazard ratio.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

4. Figure 3
Tumour mutational status as a prognostic factor for overall survival
HR=hazard ratio.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

5. Figure 4 Exploratory predictive factor analyses HR=hazard ratio.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions